Ann: Immutep completes institutional pro-rata offer & placement, page-38

You can dust those other patent’s down now Marc.
OPDIVO ,would be a nice place to start

The claims of the new patent protect Immutep’s intellectual property relating to combined therapeutic preparations comprising (a) its lead active EFT immunotherapy candidate addition to broader style claims, the granted claims include narrower claims drawn to specificand (b) an anti-PD-1 or anti-PD-L1 antibody. In combinations of efti with pembrolizumab, nivolumab,avelumab,durvalumab or atezolizumab The claims are also directed to related methods of use in the treatment of cancer.